Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders

NURMEDOV, Serdar; YILMAZ, Onat; KÖSE, Samet; Kesebir, Sermin; IBADİ, Yelda; NOYAN, CEMAL ONUR; DİLBAZ, Nesrin

Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders

Serdar NURMEDOV, (Acıbadem Hastanesi, İstanbul, Türkiye)

Yelda IBADİ, (Üsküdar Üniversitesi, Psikolji Bölümü, İstanbul, Türkiye)

CEMAL ONUR NOYAN, (Üsküdar Üniversitesi, Psikolji Bölümü, İstanbul, Türkiye)

Onat YILMAZ, (Kasımpaşa Askeri Hastanesi, Psikiyatri Bölümü, İstanbul, Türkiye)

Sermin KESEBİR, (Üsküdar Üniversitesi, Psikolji Bölümü, İstanbul, Türkiye)

Nesrin DİLBAZ, (Üsküdar Üniversitesi, Psikolji Bölümü, İstanbul, Türkiye)

Samet KÖSE (Boş)

Klinik Psikofarmakoloji Bülteni

2 0

Yıl: 2016 Cilt: 26 Sayı: 3 Sayfa Aralığı: 223 - 228 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders

Öz:

Objective: Impulsivity is an important neurobiological process that contributes to individual differences in substance use disorder vulnerability. Uric acid has been mentioned to be telated to some psychiatric disorders characterized by impulsivity. No other study has yet examined the relationship between UA plasma concentration and impulsivity in patients with substance use disorders.Methods: Eighty patients diagnosed with substance use disorders and eighty healthy controls were included. A protein-rich diet was given to all subjects for one week. Blood samples were obtained and plasma uric acid levels were recorded as in mg/dl after being centrifuged for 15 min at 3000 X g and kept at -80°C. Impulsivity was evaluated using the Turkish version of Barrat Impulsivity Scale (BIS). Results: The mean uric acid concentrations (t/?2=3.3; p<0.05) were significantly higher in the patients with substance use disorders compared to the healthy control group. Additionally, total BIS scores (t/?2=2.4; p<0.05), Attentional Impulsiveness scores (t/?2=2.1; p<0.05), and Motor Impulsiveness scores (t/?2=2.6; p<0.05) were statistically significantly higher in the patients with substance use disorder. There was a negative mild, statistically significant correlation between UA plasma levels in the patients with substance use disorder and total BIS scores (r=-0.278; p<0.05), and Motor Impulsiveness subscales scores (r=-0.302; p<0.01). Multiple linear regression analysis revealed that plasma UA levels were found to be statistically significantly associated with the Motor Impulsiveness scores in the patients with substance use disorder (p=0.007). Conclusions: This preliminary study is the first study that explores how uric acid levels were associated with impulsivity in patients with substance use disorder. Further studies with larger sample size are needed to tease out confounding factors and replicate our findings

Anahtar Kelime:

Konular: Farmakoloji ve Eczacılık

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

. Perry JL, Joseph JE, Jiang Y, Zimmerman RS, Kelly TH, Darna M, et al. Prefrontal cortex and drug abuse vulnerability: translation to prevention and treatment interventions. Brain Res Rev 2011;65(2):124-49. [CrossRef]
2. Sutin AR, Cutler RG, Camandola S, Uda M, Feldman NH, Cucca F, et al. Impulsivity is associated with uric acid: evidence from humans and mice. Biol Psychiatry 2014;75(1):31-7. [CrossRef]
3. de Wit H. Impulsivity as a determinant and consequence of drug use: a review of underlying processes. Addict Biol 2009;14(1):22-31. [CrossRef]
4. Audrain-McGovern J, Rodriguez D, Epstein LH, Cuevas J, Rodgers K, Wileyto EP. Does delay discounting play an etiological role in smoking or is it a consequence of smoking? Drug Alcohol Depend 2009 Aug 1;103(3):99-106. [CrossRef]
5. MacKillop J, Amlung MT, Few LR, Ray LA, Sweet LH, Munafò MR. Delayed reward discounting and addictive behavior: a meta-analysis. Psychopharmacology (Berl) 2011;216(3):305-21. [CrossRef]
6. Eysenck SB, Eysenck HJ. The place of impulsiveness in a dimensional system of personality description. Br J Soc Clin Psychol 1977;16(1):57-68. [CrossRef]
7. Simons JS, Carey KB. Risk and vulnerability for marijuana use problems: the role of affect dysregulation. Psychol Addict Behav 2002;16(1):72-5. [CrossRef
8. Manowitz P, Amorosa LF, Goldstein HS, Carlton PL. Uric acid level increases in humans engaged in gambling: a preliminary report. Biol Psychol 1993;36(3):223-9. [CrossRef]
9. Barrera CM, Ruiz ZR, Dunlap WP. Uric acid: a participating factor in the symptoms of hyperactivity. Biol Psychiatry 1988;24(3):344-7. [CrossRef]
10. Rösler M, Fischer R, Ammer R, Ose C, Retz W. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention deficit/ hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 2009;259(2):120-9. [CrossRef]
11. Ozten E, Kesebir S, Eryilmaz G, Tarhan N, Karamustafalioglu O. Are uric acid plasma levels different between unipolar depression with and without adult attention deficit hyperactivity disorder? J Affect Disord 2015;177:114-7. [CrossRef]
12. Machado-Vieira R, Lara DR, Souza DO, Kapczinski F. Purinergic dysfunction in mania: an integrative model. Med Hypotheses 2002;58(4):297-304. [CrossRef]
13. Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM. Adenosine and brain function. Int Rev Neurobiol 2005;63:191-270. [CrossRef]
14. Drum DE, Goldman PA, Jankowski CB. Elevation of serum uric acid as a clue to alcohol abuse. Arch Int Med 1981;141(4):477-9. [CrossRef]
15. Faller J, Fox IH. Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover. N Engl J Med 1982;307(26):1598-602. [CrossRef]
16. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005;52(1):283-9. [CrossRef]
17. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol 1995;51(6):768-74. [CrossRef]
18. Gulec H, Tamam L, Gulec MY, Turhan M, Karakus G, Zengin M, Stanford MS. Psychometric properties of the Turkish version of the barratt impulsiveness scale-11. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2008;18(4):251-8.
19. Stevens L, Verdejo-García A, Goudriaan AE, Roeyers H, Dom G, Vanderplasschen W. Impulsivity as a vulnerability factor for poor addiction treatment outcomes: a review of neurocognitive findings among individuals with substance use disorders. J Subst Abuse Treat 2014;47(1):58-72. [CrossRef
]20. Machado-Vieira R, Soares JC, Lara DR, Luckenbaugh DA, Busnello JV, Marca G, et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry 2008;69(8):1237-45. [CrossRef]
21. Lorenzi TM, Borba DL, Dutra G, Lara DR. Association of serum uric acid levels with emotional and affective temperaments. J Affect Disord 2010;121(1-2):161-4. [CrossRef]

APA	NURMEDOV S, IBADİ Y, NOYAN C, YILMAZ O, Kesebir S, DİLBAZ N, KÖSE S (2016). Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders. , 223 - 228.
Chicago	NURMEDOV Serdar,IBADİ Yelda,NOYAN CEMAL ONUR,YILMAZ Onat,Kesebir Sermin,DİLBAZ Nesrin,KÖSE Samet Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders. (2016): 223 - 228.
MLA	NURMEDOV Serdar,IBADİ Yelda,NOYAN CEMAL ONUR,YILMAZ Onat,Kesebir Sermin,DİLBAZ Nesrin,KÖSE Samet Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders. , 2016, ss.223 - 228.
AMA	NURMEDOV S,IBADİ Y,NOYAN C,YILMAZ O,Kesebir S,DİLBAZ N,KÖSE S Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders. . 2016; 223 - 228.
Vancouver	NURMEDOV S,IBADİ Y,NOYAN C,YILMAZ O,Kesebir S,DİLBAZ N,KÖSE S Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders. . 2016; 223 - 228.
IEEE	NURMEDOV S,IBADİ Y,NOYAN C,YILMAZ O,Kesebir S,DİLBAZ N,KÖSE S "Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders." , ss.223 - 228, 2016.
ISNAD	NURMEDOV, Serdar vd. "Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders". (2016), 223-228.

APA	NURMEDOV S, IBADİ Y, NOYAN C, YILMAZ O, Kesebir S, DİLBAZ N, KÖSE S (2016). Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders. Klinik Psikofarmakoloji Bülteni, 26(3), 223 - 228.
Chicago	NURMEDOV Serdar,IBADİ Yelda,NOYAN CEMAL ONUR,YILMAZ Onat,Kesebir Sermin,DİLBAZ Nesrin,KÖSE Samet Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders. Klinik Psikofarmakoloji Bülteni 26, no.3 (2016): 223 - 228.
MLA	NURMEDOV Serdar,IBADİ Yelda,NOYAN CEMAL ONUR,YILMAZ Onat,Kesebir Sermin,DİLBAZ Nesrin,KÖSE Samet Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders. Klinik Psikofarmakoloji Bülteni, vol.26, no.3, 2016, ss.223 - 228.
AMA	NURMEDOV S,IBADİ Y,NOYAN C,YILMAZ O,Kesebir S,DİLBAZ N,KÖSE S Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders. Klinik Psikofarmakoloji Bülteni. 2016; 26(3): 223 - 228.
Vancouver	NURMEDOV S,IBADİ Y,NOYAN C,YILMAZ O,Kesebir S,DİLBAZ N,KÖSE S Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders. Klinik Psikofarmakoloji Bülteni. 2016; 26(3): 223 - 228.
IEEE	NURMEDOV S,IBADİ Y,NOYAN C,YILMAZ O,Kesebir S,DİLBAZ N,KÖSE S "Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders." Klinik Psikofarmakoloji Bülteni, 26, ss.223 - 228, 2016.
ISNAD	NURMEDOV, Serdar vd. "Relationship Between Impulsivity and Plasma Uric Acid Levels in Patients with Substance Use Disorders". Klinik Psikofarmakoloji Bülteni 26/3 (2016), 223-228.